Jasper Hellweg
Stock Analyst at Argus Research
(2.74)
# 1,954
Out of 4,736 analysts
88
Total ratings
49.3%
Success rate
4.43%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $367.97 | +8.70% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $141.31 | +6.15% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $51.69 | +16.08% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $687.80 | +70.11% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $427.89 | +28.54% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $67.96 | +25.07% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $81.03 | +54.26% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $35.89 | +290.08% | 4 | Sep 13, 2023 | |
| BIIB Biogen | Maintains: Buy | $320 → $350 | $140.98 | +148.26% | 3 | May 11, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $172.61 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $167.53 | +19.38% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $21.82 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $205.69 | +40.99% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $143.16 | -30.15% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $243.99 | +20.91% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $10.22 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $152.65 | -11.56% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $31.48 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $24.45 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $272.27 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $117.36 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $60.74 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $318.47 | -51.33% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $208.98 | -56.93% | 1 | Sep 19, 2018 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $367.97
Upside: +8.70%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $141.31
Upside: +6.15%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $51.69
Upside: +16.08%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $687.80
Upside: +70.11%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $427.89
Upside: +28.54%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $67.96
Upside: +25.07%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $81.03
Upside: +54.26%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $35.89
Upside: +290.08%
Biogen
May 11, 2023
Maintains: Buy
Price Target: $320 → $350
Current: $140.98
Upside: +148.26%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $172.61
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $167.53
Upside: +19.38%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $21.82
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $205.69
Upside: +40.99%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $143.16
Upside: -30.15%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $243.99
Upside: +20.91%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.22
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $152.65
Upside: -11.56%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $31.48
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $24.45
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $272.27
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $117.36
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $60.74
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $318.47
Upside: -51.33%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $208.98
Upside: -56.93%